Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET SUV Changes and pCR to Pertuzumab/Trastuzumab in HER2+ Breast Cancer
NCT01937117Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2014
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pertuzumab in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percent Change in Standardized Uptake Value (SUV) as Measured by SULmax on [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) at Day 15. Started Jan 2014; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01937117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01937117.